Software Validation Observations in FDA Warning Letters and Consent Decrees: Patterns, Root Causes, and Remediation Expectations

Software validation observations continue to appear in FDA warning letters, inspection observations, and consent decrees across a wide range of regulated industries. While the specific technologies, systems, and business processes may differ, recurring patterns often emerge involving validation scope, change management, risk assessment, user requirements, testing rationale, electronic records, data integrity controls, and ongoing system oversight. These observations frequently involve expectations associated with 21 CFR Part 11, 21 CFR Parts 210 and 211, and software validation principles described within FDA guidance documents. In many cases, the underlying issue extends beyond a missing document or incomplete protocol and reflects broader weaknesses in how organizations make and defend software validation decisions. This session examines software validation observations through the lens of regulatory enforcement actions and remediation efforts. The discussion will focus on recurring compliance patterns, the organizational decisions that contributed to those outcomes, and the corrective actions regulators ultimately expected organizations to implement. Practical examples will be used to explore how validation weaknesses develop, how they are identified during inspections, and how organizations can strengthen validation programs before similar issues attract regulatory attention.